Trevi Therapeutics
Sandy Hook
About Trevi Therapeutics
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $311.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2025)
- Ticker: nasdaq:TRVI
- Website: trevitherapeutics.com
- Phone: 203-304-2499
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/trevi-therapeutics-45609 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.